Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis

Journal of Nanobiotechnology

Volumn 12, Issue 1, 2014, Pages

  Long, Jian Ting ^a   Cheang, Tuck yun ^a   Zhuo, Shu Yu ^a   Zeng, Rui Fang ^a   Dai, Qiang Sheng ^a   Li, He Ping ^a   Fang, Shi ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Controlled release; Doxorubicin; EGF; EGFR; Gelatin nanoparticles; Inhalation; Ligand targeting; Lung cancer

Indexed keywords

CONTROLLED RELEASE; DOXORUBICIN; EGF; EGFR; GELATIN NANOPARTICLES; INHALATION; LUNG CANCER;

CASPASE 3; DOXORUBICIN; EPIDERMAL GROWTH FACTOR CONJUGATED GELATIN NANOPARTICLE; EPIDERMAL GROWTH FACTOR DERIVATIVE; GELATIN; GELATINASE B; NANOCARRIER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; ENDOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTERNALIZATION; LUNG CANCER; LUNG CANCER CELL LINE; MOUSE; NONHUMAN; SURVIVAL RATE; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME; ANIMAL; BAGG ALBINO MOUSE; DRUG SCREENING; LUNG NEOPLASMS; METABOLISM; NEOPLASM METASTASIS; NUDE MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CASPASE 3; CELL LINE, TUMOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908090331     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/s12951-014-0037-5     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer stat. CA Cancer J Clin 2008, 61:69-90. 10.3322/caac.20107.
2. American Lung Association: Trends in Lung Cancer Morbidity and Mortality, Epidemiology and Statistics Unit: Research and Scientific Affairs. Accessed 30 June 2013, http://www.lung.org/lung-disease/lung-cancer/learning-more-about-lungcancer/understanding-lung-cancer/
3. Califano R, Abidin AZ, Peck R, Faivre-Finn C, Lorigan P. Management of small cell lung cancer: recent developments for optimal care. Drugs 2012, 72:471-490. 10.2165/11597640-000000000-00000.
4. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001, 7:3258-3262.
5. Zarogoulidis P, Chatzaki E, Porpodis K, Domvri K, Hohenforst-Schmidt W, Goldberg EP, Karamanos N, Zarogoulidis K. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine 2012, 7:1551-1572. 10.2147/IJN.S29997.
6. Roa WH, Azarmi S, Al-Hallak MH, Finlay WH, Magliocco AM, Lobenberg R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release 2011, 150:49-55. 10.1016/j.jconrel.2010.10.035.
7. Koshkina NV, Knight V, Gilbert BE, Golunski E, Roberts L, Waldrep JC. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel with 5% C02-enriched air: pharmacokinetic studies. Cancer Chemother Pharmacol 2001, 47:451-456. 10.1007/s002800000230.
8. Koshkina NV, Gilbert BE, Waldrep JC, Seryshev A, Knight V. Distribution of camptothecin after delivery as a liposome aerosol or following intra-muscular administration in mice. Cancer Chemother Pharmacol 1999, 44:187-192. 10.1007/s002800050966.
9. Gehr P, Bachofen M, Weibel ER. The normal human lung: ultrastructure and morphometric estimation of diffusion capacity. Respir Physiol 1978, 32:121-140. 10.1016/0034-5687(78)90104-4.
10. Kim K, Kim JH, Park H, Kim YS, Park K, Nam H, Lee S, Park JH, Park RW, Kim IS, Choi K, Kim SY, Kwon IC. Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release 2010, 146:219-227. 10.1016/j.jconrel.2010.04.004.
11. Sandhiya S, Dkhar SA, Surendiran A. Emerging trends of nanomedicine-an overview. Fundam Clin Pharmacol 2009, 23:263-269. 10.1111/j.1472-8206.2009.00692.x.
12. Liu J, Liao S, Diop-Frimpong B, Chen W, Goel S, Naxerova K, Ancukiewicz M, Boucher Y, Jain RK, Xu L. TGF-beta blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A 2012, 109:16618-16623. 10.1073/pnas.1117610109.
13. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316. 10.1158/1078-0432.CCR-07-1441.
14. Tang X, Varella-Garcia M, Xavier AC, Massarelli E, Ozburn N, Moran C, Wistuba LL. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res 2008, 1:192-200. 10.1158/1940-6207.CAPR-08-0032.
15. Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajima E, Xavier AC, Skokan M, Zeng C, Franklin WA, Bunn PA, Hirsch FR. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol 2009, 4:318-325. 10.1097/JTO.0b013e31819667a3.
16. Rusch V, Klimstra D, Venkatraman E, Pisters PWT, Langenfeid J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand trans-forming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997, 3:515-522.
17. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms: intermediacy of H2O2- and p53-dependent pathways. J Biol Chem 2004, 279:25535-25543. 10.1074/jbc.M400944200.
18. Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, Montharu J, Leblond V, Boisdron-Celle M, Lerondel S, Majoral C, Diot P, Racineux JL, Lemarie E. Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv 2008, 21:61-70. 10.1089/jamp.2007.0656.
19. Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Shalaby MR, Shao Y, Benz CC, Marks JD. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 2002, 1591:109-118. 10.1016/S0167-4889(02)00256-2.
20. Huang M, Ma Z, Khor E, Lim LY. Uptake of FITC-Chitosan nanoparticles by A549 Cells. Pharm Res 2002, 19:1488-1494. 10.1023/A:1020404615898.
21. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 1997, 27:1-20. 10.1002/(SICI)1097-0320(19970101)27:1<1::AID-CYTO2>3.0.CO;2-L.
22. Heiden T, Castro J, Graf BM, Tribukait B. Comparison of routine flowcytometric DNA analysis of fresh tissues in two laboratories: effects of differences in preparation methods and background models of cell cycle calculation. Cytometry 1998, 34:187-97. 10.1002/(SICI)1097-0320(19980815)34:4<187::AID-CYTO3>3.0.CO;2-D.
23. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier J-P. IL-17 Stimulates the Production and Expression of Proinflammatory Cytokines, IL- β and TNF-α by Human Macrophages. J Immunol 1998, 160:3513-3521.
24. Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE. Anticancer exffect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 1999, 44:177-86. 10.1007/s002800050965.
25. Koshkina NV, Kleinerman ES, Waldrep C, Jia S-F, Worth LL, Gilbert BE, Knight V. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosar-coma lung metastases in mice. Clin Cancer Res 2000, 6:2876-2880.